Last reviewed · How we verify
SLS-002
At a glance
| Generic name | SLS-002 |
|---|---|
| Also known as | Ketamine hydrochloride |
| Sponsor | Seelos Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002 (PHASE2)
- Department of Defense PTSD Adaptive Platform Trial - Master Protocol (PHASE2)
- A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SLS-002 CI brief — competitive landscape report
- SLS-002 updates RSS · CI watch RSS
- Seelos Therapeutics, Inc. portfolio CI